Nama Insights

Agilent Technologies (A)

Healthcare · Diagnostics Research · NYSE

S&P 500
Agilent Technologies (A) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $49.28B, a trailing price-to-earnings ratio of 28.8 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue grew 6.7% and free cash flow per share fell 14.3%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 6.3/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Rising · +14.7% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-4.5%
How far the last close sits under the highest price of the past five years.
Market cap$49.28B
Trailing P/E28.8
Price / book6.7
Price / sales6.7
FCF yield2.3%
Dividend yield0.6%
Gross margin53.8%
Operating margin22.2%
Net margin19.5%
Revenue growth (YoY)+6.7%
Revenue growth (3-yr annual)+0.5%
EPS growth (YoY)+5.5%
FCF/share growth (YoY)-14.3%
Beta1.2
ExchangeNYSE
SectorHealthcare
IndustryDiagnostics Research

A earnings

Next report: Nov 23, 2026 (Q4 2026, EPS estimate $1.73). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Aug 26, 2026 $1.62 $1.49 +8.7% $1.88B
Q2 2026 May 27, 2026 $1.49 $1.41 +5.7% $1.83B
Q1 2026 Feb 25, 2026 $1.36 $1.37 -0.7% $1.80B
Q4 2025 Nov 24, 2025 $1.59 $1.58 +0.6% $1.86B

A analyst price target

Median target $185.00 from 20 analysts, ranging $155.00 – $200.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $257.42B 28.1
DHR Danaher $161.86B 27.6
IDXX IDEXX Laboratories $53.26B 45.6
WAT Waters $44.93B 31.8
IQV IQVIA $44.80B 21.2
NTRA Natera $44.78B —
MTD Mettler-Toledo International $34.51B 37.2
ILMN Illumina $32.23B 40.6
Explore live A data on Nama Insights →

Recent Congressional trades

Agilent Technologies trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Julie Johnson House Sell $1,001 - $15,000 Aug 5, 2026
Thomas H Tuberville Senate Sell $1,001 - $15,000 Aug 5, 2026
Lisa McClain House Sell $1,001 - $15,000 Aug 13, 2025
Lisa McClain House Buy $1,001 - $15,000 Aug 13, 2025
Jefferson Shreve House Sell $15,001 - $50,000 Jun 22, 2025
Rob Bresnahan House Buy $1,001 - $15,000 May 31, 2025
Julie Johnson House Sell $1,001 - $15,000 May 14, 2025
Jefferson Shreve House Buy $15,001 - $50,000 May 8, 2025
Rob Bresnahan House Sell $1,001 - $15,000 Apr 28, 2025
Julie Johnson House Sell $1,001 - $15,000 Apr 14, 2025
Jefferson Shreve House Sell $15,001 - $50,000 Apr 11, 2025
James M Inhofe Senate Sell $50,001 - $100,000 —

A FAQ

Is A a buy?
Nama's AI scorecard currently rates Agilent Technologies Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is A's P/E ratio?
Agilent Technologies trades at a trailing price-to-earnings ratio of 28.8.
When does A report earnings?
Agilent Technologies's next scheduled report is on Nov 23, 2026. Analysts expect EPS of $1.73.
What is the A price target?
The median analyst price target from 20 analysts is $185.00, with a range of $155.00 – $200.00.
Is A Shariah compliant?
Nama's AAOIFI-style screen reads Agilent Technologies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does A pay a dividend?
Yes — Agilent Technologies's dividend yield is 0.6%.